CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The IMMUNONET project aims to evaluate the efficacy of NP137, a monoclonal antibody that targets NETRIN-1, in overcoming resistance to immune checkpoint inhibitors in cancer treatment. The goal is to improve patient response rates to existing therapies.
Immune Checkpoint Inhibitors (ICPIs) have recently revolutionized the treatment and management of cancer.
Yet, progress recorded and impact on long-term survival affect only a limited fraction of patients, as most of the cancer patients do not or incompletely respond to ICPIs due to primary or secondary resistance to these treatments.NETRIS Pharma is an innovative biotech company based in Lyon.
The company has developed NP137, a humanized monoclonal antibody targeting NETRIN-1, able to drive tum…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
